Otenabant

Otenabant

Systematic (IUPAC) name
1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide
Identifiers
CAS Number	686344-29-6
ATC code	none
PubChem	CID 10052040
ChemSpider	8227602
UNII	J8211Y53EF
KEGG	D09362
ChEMBL	CHEMBL562668
Chemical data
Formula	C25H25Cl2N7O
Molar mass	510.4 g/mol
SMILES CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N
InChI InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35) Key:UNAZAADNBYXMIV-UHFFFAOYSA-N
(what is this?)  (verify)

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB₁ antagonist.^[1] It was developed by Pfizer for the treatment of obesity,^[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.^[3]

See also

• Cannabinoid receptor antagonist

References

1. Kim, M.; et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057
2. Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
3. http://www.pfizer.com